Sign inJoin waitlistJoin the waitlist

Lucy Mastrandrea

Associate Program Director · University at Buffalo School of Medicine

Credentials: · · · · ·

History

University at Buffalo School of Medicine
Present
Endocrinology/Diabetes, University at Buffalo · University at Buffalo School of Medicine
Present
Endocrinology/Diabetes Division · University at Buffalo School of Medicine
Present

Pediatric Endocrinology
University at Buffalo School of Medicine
2002–2005
Pediatrics
University at Buffalo School of Medicine
1999–2000
Biochemistry, University at Buffalo
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
1995–1999
Biochemistry, Manhattan College, Summa Cum Laude
1986–1990

Research

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Gut · 2018 · 621 citations
Once-Weekly Semaglutide in Adolescents with Obesity
New England Journal of Medicine · 2022 · 531 citations
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
New England Journal of Medicine · 2020 · 529 citations

Teresa Quattrin
20 papers
Mark Greenawald
5 papers
Alan Posner
4 papers
IM
Indrajit Majumdar
4 papers · 2 as a resident
CA
Christine Albini
3 papers
John Butsch
3 papers
PH
Paula Hale
3 papers
RB
Robert Baker
3 papers
Susan Baker
3 papers
Aaron Hoffman
2 papers
Grazia Aleppo
2 papers
Kathleen Bethin
2 papers

Clinical trials

Slow Digestible Carbohydrates and Exercise in Adolescents With Type 1 Diabetes
Principal investigator · Withdrawn
State University of New York at Buffalo
2023–2025
Liraglutide in Adolescents With Type 1 Diabetes
Principal investigator · Completed · Phase 3
University at Buffalo
2012–2023
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2032
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Site PI · Recruiting · Phase 1, Phase 2
COUR Pharmaceutical Development Company, Inc.
2025–2027